戻る
Tiziana Life Sciences Ltd (TLSA)価格
TLSA 株価推移チャート
TLSA 収入
Tiziana Life Sciences Ltd
$1.63
-1.8%
$-0.03
終値： Jan 23, 16:00:00 GMT-5
$1.61
-1.22%
$-0.01
アフターマーケット：Jan 23, 20:00:00 GMT-5
主要データ
前終値
$1.66
始値
$1.66
当日レンジ
$1.58 - $1.66
52週レンジ
$0.63 - $2.6
取引高
214.3K
平均取引高
317.7K
1株当たり利益(TTM)
-0.11
配当利回り
--
時価総額
$191.3M
TLSAとは何ですか？
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).